|
|
 Afeyan, Noubar Managing Partner and Chief Executive Officer, Flagship Ventures Noubar Afeyan is Managing Partner and CEO of Flagship Ventures, a firm he co-founded in 2000 that focuses on inventing, launching, funding and building new ventures. He is also a Senior Lecturer at MIT where he has taught courses on entrepreneurship and innovation since 2000. In addition, he recently joined Harvard University’s Wyss Institute for Biologically Inspired Engineering as a visiting scholar.  Dr. Afeyan has authored numerous scientific publications and patents since earning his Ph.D. in Biochemical Engineering from MIT in 1987. During his 23-year-long career as inventor, entrepreneur, CEO and venture capitalist, Dr. Afeyan has co-founded and helped build over twenty life science, technology and energy startups. Currently Dr. Afeyan serves on a number of public and private company boards and he is a member of several advisory boards including the Deshpande Center for Technological Innovation at MIT, the Whitehead Institute at MIT, the SKOLKOVO School of Management in Moscow and the National Competitiveness Foundation of Armenia. Dr. Afeyan’s past and current ventures include: PerSeptive Biosystems, ChemGenics Pharmaceuticals, EXACT Sciences, Color Kinetics, Celera Genomics, Affinnova, Adnexus Therapeutics, BG Medicine, LS9 and Joule Unlimited.
|
|
Video Length: 4320
Date Found: May 18, 2011
Date Produced: May 18, 2011
|
|
 MIT TechTV |
July 13, 2011
|
 MIT TechTV |
July 07, 2011
|
 MIT TechTV |
June 27, 2011
The emerging cleantech venture`s pilot has been supported by government grants now it is time to scale. Cleantech requires significant funding, often larger than traditional vc`s are structured to support. How does a cleantech venture scale to grow? Hear from national project developer ...
|
 MIT TechTV |
June 27, 2011
Three leading New York venture capital firms will provide their strategies for 2011. Understanding venture capital firms’ strategies is critical in order to obtain venture capital. Prior to the panel discussion, PwC will present a summary of the 3rd quarter 2010 MoneyTree Report. The MoneyTree ...
|
 MIT TechTV |
June 27, 2011
With the recent passage of healthcare reform legislation, corporate consolidations, and a `get tough` policy at the FDA, it is difficult to tell what the commercial healthcare landscape will look like during the next five years. A distinguished panel of experts representing biopharmaceuticals, ...
|
|
|
|
|
|
Featured
Content
Featuring websites that enhance the internet user’s experience.
|